Sector News

AstraZeneca oncology head jumps ship to become Innate CEO

December 20, 2016
Life sciences

AstraZeneca is losing its head of oncology, Mondher Mahjoubi, who is departing to lead French biotech company Innate Pharma.

Innate said on Monday that Mahjoubi would take over as chief executive on Dec. 30, replacing Herve Brailly who is moving on to become chairman of the supervisory board.

The loss of Mahjoubi is a setback for AstraZeneca, given the British drugmaker’s focus on new cancer treatments. Mahjoubi previously worked at Roche’s (ROG.S) Genentech unit before joining AstraZeneca, where he has helped lead oncology strategy.

His departure comes ahead of key clinical trial read-outs for the company’s experimental immunotherapy drugs.

AstraZeneca said Mahjoubi’s successor would be announced shortly.

For Mahjoubi, the move to Innate offers the opportunity to run a company that specialises in immuno-oncology, which is now transforming the fight against several different types of cancer.

Innate said he would be paid a base salary of 470,000 euros ($490,000). He will also get free shares in the company and be eligible for pay and share bonuses, if certain targets were met.

Shares in Innate were 4 percent higher by 1230 GMT while AstraZeneca slipped 1.4 percent.

By Ben Hirschler

Source: Reuters

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.